Author | Wayne Kuznar | OncLive

Author | Wayne Kuznar


Nivolumab/SBRT Data Leave Role of Radiation Unclear in RCC

February 17, 2020

Stereotactic body radiotherapy combined with nivolumab was associated with “high” disease control and overall survival rates in a phase II study of pretreated patients with metastatic renal cell carcinoma; however, the combination did not meet the primary endpoint of overall response rate.

Nivolumab Neoadjuvant Regimen Nears 50% pCR in MIBC

February 16, 2020

The neoadjuvant regimen of nivolumab combined with gemcitabine and cisplatin achieved a pathologic nonmuscle-invasive rate of 66% and a pathologic complete response rate of 49% in patients with muscle-invasive bladder cancer.

Neoadjuvant Durvalumab/Olaparib Active in Muscle-Invasive Bladder Cancer

February 15, 2020

A neoadjuvant regimen of durvalumab plus olaparib induced a pathologic complete response rate of 50% in patients with muscle-invasive bladder carcinoma.

Apalutamide Delivers PFS2 Benefit in mCSPC, Regardless of Subsequent Therapy

February 14, 2020

Adding apalutamide to androgen deprivation therapy reduced the risk of second progression or death by 34% compared with ADT alone in patients with metastatic castration-sensitive prostate cancer.